Chapter 4 Multitasking by Exploitation of Intracellular Transport Functions
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The MHC Class I-related receptor, FcRn, transports antibodies of the immunoglobulin G (IgG) class within and across a diverse array of different cell types. Through this transport, FcRn serves multiple roles throughout adult life that extend well beyond its earlier defined function of transcytosing IgGs from mother to offspring. These roles include the maintenance of IgG levels and the delivery of antigen in the form of immune complexes to degradative compartments within cells. Recent studies have led to significant advances in knowledge of the intracellular trafficking of FcRn and (engineered) IgGs at both the molecular and cellular levels. The engineering of FcRn–IgG (or Fc) interactions to generate antibodies of increased longevity represents an area of active interest, particularly in the light of the expanding use of antibodies in therapy. The strict pH dependence of FcRn–IgG interactions, with binding at pH 6 that becomes essentially undetectable as near neutral pH is approached, is essential for efficient transport. The requirement for retention of low affinity at near neutral pH increases the complexity of engineering antibodies for increased half-life. Conversely, engineered IgGs that have gained significant binding for FcRn at this pH can be potent inhibitors of FcRn that lower endogenous IgG levels and have multiple potential uses as therapeutics. In addition, molecular studies of FcRn–IgG interactions indicate that mice have limitations as preclinical models for FcRn function, primarily due to cross-species differences in FcRn-binding specificity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Tie2-Cre Transgenic Mice: A New Model for Endothelial Cell-Lineage Analysis in Vivo
Kisanuki, Y. Y., Hammer, R. E., Miyazaki, J.-I., Williams, S. C., Richardson, J. A., & Yanagisawa, M. (2001) · Developmental Biology · doi:10.1006/dbio.2000.0106 · Cited by 1,241
EEA1 links PI(3)K function to Rab5 regulation of endosome fusion
Simonsen, A., Lippe, R., Christoforidis, S., Gaullier, J.-M., Brech, A., Callaghan, J., Toh, B.-H., Murphy, C., Zerial, M., & Stenmark, H. (1998) · Nature · doi:10.1038/28879 · Cited by 1,133 · cited 2×
“…known to be involved in recycling cargo from sorting endosomes to the plasma membrane (Daro et al., 1996; Green et al., 1997; Sönnichsen et al., 2000; Ullrich et al., 1996; van der Sluijs et al., 1992), whereas Rab5 is an early endosomal marker (Christoforidis et al., 1999; Simonsen et al., 1998).”
BackgroundCurvature of clathrin-coated pits driven by epsin
Ford, M. G. J., Mills, I. G., Peter, B. J., Vallis, Y., Praefcke, G. J. K., Evans, P. R., & McMahon, H. T. (2002) · Nature · doi:10.1038/nature01020 · Cited by 1,019
Rabs and their effectors: achieving specificity in membrane traffic
Grosshans, B. L., Ortiz, D., & Novick, P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601617103 · Cited by 1,005 · cited 2×
“…such as soluble NSF attachment protein receptors (SNAREs) that usually exist as transmembrane receptors ( Jahn et al., 2003), Rabs are key regulators of fusion events between different membranous compartments (Grosshans et al., 2006; Miaczynska and Zerial, 2002; Somsel and Wandinger-Ness, 2000).”
BackgroundThe Rab5 effector EEA1 is a core component of endosome docking
Christoforidis, S., McBride, H. M., Burgoyne, R. D., & Zerial, M. (1999) · Nature · doi:10.1038/17618 · Cited by 854 · cited 2×
“…known to be involved in recycling cargo from sorting endosomes to the plasma membrane (Daro et al., 1996; Green et al., 1997; Sönnichsen et al., 2000; Ullrich et al., 1996; van der Sluijs et al., 1992), whereas Rab5 is an early endosomal marker (Christoforidis et al., 1999; Simonsen et al., 1998).”
BackgroundAn Fc receptor structurally related to MHC class I antigens
Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729 · cited 6×
“The cloning of the gene for rat FcRn in 1989 unexpectedly revealed that this receptor comprises an a-chain that is homologous to MHC Class I a-chains, and the 12 kDa component is b2-microglobulin (b2m) (Simister and Mostov, 1989).”
BackgroundInfluentialChaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640 · cited 4×
“FcRn for in vivo persistence (Andersen et al., 2006; Chaudhury et al., 2003) can also be exploited by using therapeutic reagents fused to albumin binding peptides or Ig domains with the aim of generating longer lived therapeutics (Dennis et al.”
BackgroundInfluentialEngineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407 · cited 15×
“The ‘‘intrinsic’’ consequences of an Fc mutation on the in vivo half-life of an IgG or Fc fragment itself will impact the ‘‘extrinsic’’ effects of this engineered IgG/Fc on the lowering of endogenous IgG levels, since they will determine the in vivo longevity of a potential Abdeg.”
BackgroundMethodInfluentialSelf-citationCrystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
Cited by
Particle shape enhances specificity of antibody-displaying nanoparticles
Barua, S., Yoo, J.-W., Kolhar, P., Wakankar, A., Gokarn, Y. R., & Mitragotri, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216893110 · Cited by 523
“A are used routinely in various analytical, diagnostic, and therapeutic applications, including cell and protein sorting (1), in vitro assays (2), in vivo imaging (3), and targeted delivery of therapeutics for the treatment of various diseases, including cancer (4), arthritis (5), and allergies (6).”
MethodAlbumin as a versatile platform for drug half-life extension
Sleep, D., Cameron, J., & Evans, L. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.023 · Cited by 485
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
Hogarth, P. M., & Pietersz, G. A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2909 · Cited by 348
FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
Pyzik, M., Rath, T., Lencer, W. I., Baker, K., & Blumberg, R. S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403014 · Cited by 298
Metadata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chapter 4 Multitasking by Exploitation of Intracellular Transport Functions. https://app.cochat.ai/papers/10.1016/s0065-2776(09)03004-1
- The paper
- Ward, E. S., & Ober, R. J. (2009). Chapter 4 Multitasking by Exploitation of Intracellular Transport Functions. Advances in Immunology. https://doi.org/10.1016/s0065-2776(09)03004-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.